Plasma therapy: a passive resistance against the deadliest

Plasma therapy: a passive resistance against the deadliest

Convalescent plasma therapy provides a useful therapeutic tool to treat infectious diseases, especially where no specific therapeutic strategies have been identified. The ongoing pandemic puts back the spotlight on this age-old method as a viable treatment option. In this review, we discuss the usag...

Full description

Bibliographic Details
Main Authors:	Anita Hansda, Debarati Biswas, Aishwarya Bhatta, Nishant Chakravorty, Gayatri Mukherjee
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-04-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	convalescent plasma neutralizing antibodies (nabs) intravenous immunoglobulin (ivig)
Online Access:	http://dx.doi.org/10.1080/21645515.2021.2006026

Similar Items

Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection
by: Steven Rockman, et al.
Published: (2017-05-01)

The therapeutic window of intravenous immunoglobulin (IVIG) and its correlation with clinical outcomes in Kawasaki disease: a systematic review and meta-analysis
by: Zheng Li, et al.
Published: (2023-04-01)

Mechanism of increased efficacy of recombinant Fc‐μTP‐L309C compared to IVIg to ameliorate mouse immune thrombocytopenia
by: Bonnie J.B. Lewis, et al.
Published: (2021-11-01)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
by: Wei Zhang, et al.
Published: (2023-11-01)

To which extent a convalescent plasma therapy could be a benefit for COVID-19 patients?
by: Abdelmonem Ali, et al.
Published: (2020-11-01)

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
by: Maria R. Farcet, et al.
Published: (2022-08-01)

Immunoglobulin replacement therapies in inborn errors of immunity: a review
by: Archan Sil, et al.
Published: (2024-02-01)

Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients
by: MEENU BAJPAI, et al.
Published: (2022-09-01)

Antibody diversity in IVIG: Therapeutic opportunities for novel immunotherapeutic drugs
by: Stephan von Gunten, et al.
Published: (2023-03-01)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
by: Daniele Focosi, et al.
Published: (2022-10-01)

Convalescent plasma: A potential therapeutic option for COVID-19 patients
by: Swee Li Ng, et al.
Published: (2020-01-01)

Pregnancy associated anti-TIF1 dermatomyositis responsive to intravenous immunoglobulin
by: Jason Kieffer, MD, et al.
Published: (2024-03-01)

Potential intravenous immunoglobulin-induced optic disc edema
by: Anna K. Britton, et al.
Published: (2022-09-01)

The Natural History of Untreated Primary Hypogammaglobulinemia in Adults: Implications for the Diagnosis and Treatment of Common Variable Immunodeficiency Disorders (CVID)
by: Rohan Ameratunga, et al.
Published: (2019-07-01)

Speculations of Immunotherapy in COVID-19 Patients with Practical Applications During Childhood and Pregnancy
by: Hayder Al-Momen, et al.
Published: (2020-07-01)

Convalescent (Immune) Plasma Followed by Intravenous Immunoglobulin Infusion in an Adolescent with Severe COVID-19
by: Öner Özdemir, et al.
Published: (2021-08-01)

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study
by: Luther A. Bartelt, et al.
Published: (2022-10-01)

The use of furosemide during Intravenous Immunoglobulin therapy should not always be considered contraindicated
by: Serdar EFE, et al.
Published: (2024-02-01)

In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors
by: Gabriel Rojas-Jiménez, et al.
Published: (2022-01-01)

Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions
by: Tara Klemencic Kozul, et al.
Published: (2022-07-01)

Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia
by: Nina Nurarifah, et al.
Published: (2021-11-01)

Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo
by: Anne K. Braczynski, et al.
Published: (2022-03-01)

Immunoglobulin: production, mechanisms of action and formulations
by: Marcia Cristina Zago Novaretti, et al.
Published: (2011-10-01)

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy
by: Mohamad Mroué, et al.
Published: (2024-01-01)

Retrospective correlation analysis of plasma Immunoglobulin G and clinical performance in CIDP
by: Lars Kjøbsted Markvardsen, et al.
Published: (2019-05-01)

Immunoglobulin utilization in Canada: a comparative analysis of provincial guidelines and a scoping review of the literature
by: Megan Harmon, et al.
Published: (2023-09-01)

Injection of intravenous immunoglobulin (IVIg) for the treatment of Coronavirus induced cytokine storm
by: Farahnoosh Farnood, et al.
Published: (2022-12-01)

Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates
by: Günalp Uzun, et al.
Published: (2023-06-01)

Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection
by: Marius Andreas Koslik, et al.
Published: (2022-01-01)

Characterization of antibodies in human immunoglobulin products from different regions worldwide
by: Alexandra Serra, et al.
Published: (2021-03-01)

Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients
by: Dorota Kwapisz, et al.
Published: (2023-07-01)

Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients
by: Rui Zhang, et al.
Published: (2023-06-01)

Factors predicting poor outcome in patients with fulminant Guillaine-Barré syndrome
by: Nandagopal Nithyashree, et al.
Published: (2014-01-01)

Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and intravenous immunoglobulin (IVIG): comprehensive open-label trial in ten children
by: Parisa Hajjari, et al.
Published: (2022-08-01)

Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease
by: Elizabeth A. Fitzpatrick, et al.
Published: (2020-03-01)

Intravenous Immunoglobulin Therapy for Critically Ill COVID-19 Patients With Different Inflammatory Phenotypes: A Multicenter, Retrospective Study
by: Yan Chen, et al.
Published: (2022-01-01)

Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial
by: Saori Fukui, et al.
Published: (2021-07-01)

IVIG – A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin
by: Kelley Coffman, et al.
Published: (2017-01-01)

Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations
by: Caiqin Hu, et al.
Published: (2022-01-01)

“Multisystem Inflammatory Syndrome in Children” (MIS-C) after COVID-19 Infection in the Metropolitan Area of Nuremberg-Erlangen, Germany—Expectations and Results of a Two-Year Period
by: Steven Hébert, et al.
Published: (2023-08-01)